Back

Prevalence and prognostic impact of coronary artery disease in heart failure with preserved ejection fraction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Novel biomarkers for risk assessment of your patient with heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mikio Shiba

Osaka Keisatsu Hospital, Osaka (Japan)

7 More presentations in this session

Presentation thumbnail
Association of blood biomarkers with cardiovascular and kidney adverse outcomes in people with heart failure with preserved ejection fraction
Assistant Professor B. Roehm (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Thyroid function and outcomes in heart failure with mildly reduced ejection fraction: insights from a large, retrospective registry
Doctor M. Abumayyaleh (Mannheim, DE)
Abstract Slides
Presentation thumbnail
Clinical determinants of MYDGF in a heart failure population - results from the Emperor biomarker program
Doctor M. Panova-Noeva (Ingelheim am Rhein, DE)
Abstract Slides Video
Presentation thumbnail
One-year prognosis according to BMI among heart failure patients with preserved and mildly reduced ejection fraction in Polish cohort - insights from HF-POL registry
Doctor E. Kazimierczyk (Bialystok, PL)
Abstract Slides Video
Presentation thumbnail
Quantifying left atrial mechanical work in patients with atrial fibrillation with or without heart failure and preserved ejection fraction undergoing pulmonary vein isolation
Mr L. Semmler (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Novel biomarkers for risk assessment of your patient with heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Heart failure phenotypes and outcomes
thumbnail
Congress Session
Delving deeper into HFpEF
thumbnail
Congress Session
Registries on incident and prevalent heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources